Are the "Peier 13" selling well?

More than three months after it was approved for marketing, Kangtai Bio's dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine - Weiminfeibao recently received its first injection in Guangzhou, which also means that in the 13-valent pneumococcal conjugate vaccine market, One more "spoiler"
.

"1+1" market competition pattern

As one of the world's best-selling blockbuster vaccine varieties, the 13-valent pneumonia conjugate vaccine has attracted widespread market attention
.

The world's first 13-valent pneumonia vaccine, the original vaccine (trade name Peier 13, hereinafter referred to as Peier), was developed by Pfizer for the prevention of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, Invasive diseases caused by 14, 18C, 19A, 19F, 23F (including bacteremic pneumonia, meningitis, sepsis and bacteremia, etc.
), which were approved by the US FDA and EU in 2010, and launched in China in 2016 Approved for marketing, it is used for infants aged 6 weeks to 15 months
.

For Pfizer, Peier is a veritable "cash cow".
In its annual revenue structure, Peier's sales performance has always accounted for a large proportion.
As early as 2014, Peier once set a record of 4.
5 billion US dollars for Pfizer.
(approximately 28.
7 billion yuan), the global sales performance of Peier from 2017 to 2020 reached more than 5 billion US dollars.
Specifically, it brought Pfizer US$ 5.
601 billion, US$ 5.
802 billion, With a revenue of US$5.
847 billion and US$5.
850 billion, in the first half of 2021, Peier received about US$2.
7 billion in gold, and it is still one of the best-selling vaccine products in the world.
In July 2021, Pfizer announced that the US FDA has approved Prevnar 20 (Prevnar 20).
Pneumococcal 20-valent conjugate vaccine) is listed, which is an upgraded version of Peier
.

Before the domestic 13-valent pneumonia conjugate vaccine was launched, due to the strong demand and the monopoly of the product in the market, even if the price was high (698 yuan per dose), Peier has been in a state of short supply in the Chinese market, and there have been frequent "out of stock", Relevant statistics show that in 2019, Peier's batch issuance was 4.
755 million pieces, although it has increased by 24% compared with the same period in 2018, but according to the proportion of 14.
65 million newborns in 2019, Peier's penetration rate is still Very low.
Based on 4 injections (sticks) per newborn, the supply gap exceeds 50 million pieces.
However, with the approval of the domestic 13-valent pneumonia conjugate vaccine product, the market pattern has changed
.

At the end of 2019, Watson Bio's 13-valent pneumococcal polysaccharide conjugate vaccine (trade name Woanxin) was approved for marketing, thus breaking Pfizer's import monopoly and becoming the first domestically produced and the second 13-valent pneumococcal conjugate vaccine in the world.
Xin is suitable for children from 6 weeks to 5 years old, 3 doses for 6 weeks to 6 months old, 1 booster for 12-15 months old; 2 doses for 7-11 months old children, 1 booster for 12 months old children; 12- Children aged 23 months are vaccinated with 2 doses; children aged 2-5 are vaccinated with 1 dose
.

The dual advantages have allowed Wo Anxin to gain rapid market volume.
According to the batch issuance data of the China Inspection and Quarantine Institute, among the batch issuance of over 10 million doses in 2020, Watson Bio reached 4.
4651 million doses and Pfizer 6.
4235 million doses.
It means that Watson Bio grabs more than 40% of the market from it
.

In 2021, Wo Anxin's performance will continue to rise.
Watson Bio's semi-annual report shows that Wo Anxin's revenue in the first half of the year was 989 million yuan, a year-on-year increase of 779.
53%, accounting for 73.
31% of the company's revenue, and achieving a gross sales margin of 94.
19%
.

The market competition for the 13-valent pneumonia conjugate vaccine continues
.

Kangtai Bio entered the bureau

In September 2021, the 13-valent pneumococcal polysaccharide conjugate vaccine Weiminfeibao developed by Beijing Minhai Biological, a subsidiary of Kangtai Biology, was officially approved for listing, which also broke the "1+1" market competition between Pfizer and Watson Biology.
, becoming the third 13-valent pneumonia conjugate vaccine product approved for marketing in the world
.

According to Kangtai Biology, Viminfeibao is the world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine.
It adopts a dual-carrier process, which can effectively prevent a single carrier protein from competing with helper T cells and inhibit the immune response of polysaccharides.
The vaccine phase III clinical trial data showed that the antibody positive rate and geometric mean titer of antibodies against 13 serotypes of pneumococcus were non-inferior to similar imported products.
The 13-valent pneumococcal vaccine of Weimin Feibao is aimed at 6 weeks to 5 years old.
(Before the 6th birthday) infants and children have good results, greatly extending the window period of 13-valent vaccination, so that more domestic children can be protected by the vaccine
.

In terms of price, Weimin Feibao is priced at 485 yuan per dose (according to the different provincial vaccination service fees and cold chain costs, the final consumer vaccination price will be slightly different), which is not only more than 30% lower than the price of Peier, but also more expensive more than 10% lower
.

Not only that, Kangtai Biology may also welcome more competitors.

According to Southwest Securities' estimates on the newborn market, assuming that there are 14 million newborns each year in China, it is expected that the market penetration rate of this product in infants and young children may reach 30% in the future.